TABLE 1.
Patients' feature at baseline (week 0)
| Number of patients | 39 |
| Sex | |
| Male | 26 (66.7%) |
| Female | 13 (33.3%) |
| Mean age (years) | 50.5 ± 13.7 |
| Mean duration of psoriasis (years) | 17.2 ± 9.7 |
| Psoriatic arthritis | 15 (38.5%) |
| Nail psoriasis | 9 (23.1%) |
| Psoriasis activity | |
| PASI | 13.7 ± 5.8 |
| BSA | 21.9 ± 14.6 |
| NAPSI | 9.3 ± 4.7 |
| Comorbidities | |
| Hypertension | 17 (43.6%) |
| Obesity | 16 (41.0%) |
| Diabetes | 13 (33.3%) |
| Dyslipidemia | 9 (23.1%) |
| Cardiopathy | 5 (12.8%) |
| Depression | 3 (7.7%) |
| Hypothyroidism | 2 (5.1%) |
| Previous systemic treatments (conventional and small‐molecules) | |
| Methotrexate | 29 (74.4%) |
| Cyclosporine | 26 (66.7%) |
| Nb‐UVB phototherapy | 11 (28.2%) |
| Acitretin | 5 (12.8%) |
| Apremilast | 3 (7.7%) |
| Previous biologic treatments | |
| Anti‐TNFα | |
| Adalimumab | 12 (30.8%) |
| Etanercept | 9 (23.1%) |
| Infliximab | 7 (17.9%) |
| Golimumab | 5 (12.8%) |
| Certolizumab | 4 (10.3%) |
| Anti‐IL12/23 | 17 (43.6%) |
| Anti‐IL17 | |
| Ixekizumab | 26 (66.7%) |
| Secukinumab | 24 (61.5%) |
| Brodalumab | 2 (5.1%) |
| Average duration of treatment (months) | |
| Anti‐TNFα | |
| Adalimumab | 7.5 ± 6.4 |
| Etanercept | 10.7 ± 11.8 |
| Infliximab | 5.3 ± 4.8 |
| Golimumab | 11.0 ± 11.2 |
| Certolizumab | 6.1 ± 2.9 |
| Anti‐IL12/23 | 27.8 ± 18.1 |
| Anti‐IL17 | |
| Ixekizumab | 14.7 ± 8.9 |
| Secukinumab | 12.8 ± 10.8 |
| Brodalumab | 4.3 ± 2.6 |
Note: PASI 90 and PASI 100 were achieved at week 16 by 24 (61.5%) and 14 (35.9%) patients, respectively and by 33 (84.6%) and 25 (64.1%) patients at week 52.
Abbreviations: BSA, body surface area; NAPSI, nail psoriasis severity index (NAPSI); Nb‐UVB, narrow band – ultraviolet B; PASI, psoriasis activity severity index.